Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m…
Featured
-
-
ASCO25: Kura’s Phase II ziftomenib results trigger NDA acceptance from FDA
A November 2025 PDUFA date has been set for Kura Oncology’s oral acute myeloid leukaemia (AML) drug ziftomenib following the…
-
ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia
Amgen’s Nplate (romiplostim) has demonstrated efficacy in treating thrombocytopaenia among gastrointestinal (GI) cancer patients, as Phase III RECITE results are…
-
ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups
Updated analysis showed Carvykti (ciltacabtagene autoleucel) improved survival for multiple myeloma patients regardless of their cytogenetic risk or prior lines…
-
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC
Pfizer’s Braftovi (encorafenib) combination therapy was shown to reduce the risk of death by nearly half compared to standard of…
-
Capitalising on UK’s goal to become a world-leading clinical trial destination
Representatives of industry and regulation will meet in June to discuss paths forward for the UK’s clinical trials sector following…
-
Can pharma tariffs “Make America Manufacture Again”?
As President Trump continues to signal import tariffs on pharmaceuticals to bolster US manufacturing, experts warn this could hike costs…
-
Pharma’s AI prospects get nudged into the future with EU’s AI act
The EU Artificial Intelligence (AI) Act may protect citizens, but some experts in the life sciences industry are worried about…
-
Investors insist halted biotech IPOs will return in 2025
Investors remain optimistic for a return of biotech IPOs in 2025 despite a market downturn following the announcement of US…
-
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a…
